case_images: PMC6745160_01
case_images: CEA level according to chronological date. The start dates of the patient's most recent chemotherapy and immunotherapy regimens are marked for reference.
case_images: CRIONM2019-3847672.001.jpg
case_images: PMC6745160_01_CRIONM2019-3847672.001.jpg
case_images: fig1
case_images: CEA level and clinical improvement. CEA decreased to within normal limits, and his weight increased over the course of pembrolizumab treatment (Figures 1 and 2).
case_images: Weight according to chronological date. The start dates of the patient's most recent chemotherapy and immunotherapy regimens are marked for reference.
case_images: CRIONM2019-3847672.002.jpg
case_images: PMC6745160_01_CRIONM2019-3847672.002.jpg
case_images: fig2
case_images: CEA level and clinical improvement. CEA decreased to within normal limits, and his weight increased over the course of pembrolizumab treatment (Figures 1 and 2).
case_images: CT contrast imaging before (a) (October 8, 2015) and after (b) (February 1, 2019) administration of pembrolizumab. The black arrow in panel (a) indicates a large retroperitoneal lymph node conglomerate which compressed the inferior vena cava, encased the aorta, and invaded the left renal vein. The lymph node conglomerate has since been reduced to small dense calcifications as seen in panel (b).
case_images: CRIONM2019-3847672.003.jpg
case_images: PMC6745160_01_CRIONM2019-3847672.003.jpg
case_images: fig3
case_images: CEA remains within normal limits and surveillance CT scan in February 2019 showed no evidence of metastatic disease, indicating a remarkable response when compared to the CT prior to the initiation of immunotherapy (Figure 3).